Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4

Biochemical and Biophysical Research Communications

Volumn 427, Issue 3, 2012, Pages 618-622

  Lee, Kwang Min ^a   Lee, Jongwon ^a   Park, Chul Seung ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

Binding protein; Cereblon; Proteasome activity; Proteasome subunit beta type 4

Indexed keywords

BINDING PROTEIN; CEREBLON PROTEIN; PROTEASOME; PROTEASOME SUBUNIT BETA TYPE 4; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SUBUNIT; TUMOR CELL LINE;

CELL LINE; CHYMOTRYPSIN; DOWN-REGULATION; HEK293 CELLS; HUMANS; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84867843856     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.09.108     Document Type: Article

References (21)

1. Higgins J.J., Pucilowska J., Lombardi R.Q., Rooney J.P. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 2004, 63:1927-1931.
2. Jo S., Lee K.H., Song S., Jung Y.K., Park C.S. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J. Neurochem. 2005, 94:1212-1224.
3. Hohberger B., Enz R. Cereblon is expressed in the retina and binds to voltage-gated chloride channels. FEBS Lett. 2009, 583:633-637.
4. Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., Yamaguchi Y., Handa H. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327:1345-1350.
5. Lee K.M., Jo S., Kim H., Lee J., Park C.S. Functional modulation of AMP-activated protein kinase by cereblon. Biochim. Biophys. Acta 1813, 2011:448-455.
6. Coux O., Tanaka K., Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 1996, 65:801-847.
7. Arendt C.S., Hochstrasser M. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc. Nat. Acad. Sci. USA 1997, 94:7156-7161.
8. Heinemeyer W., Ramos P.C., Dohmen R.J. The ultimate nanoscale mincer: assembly, structure and active sites of the 20S proteasome core. Cell. Mol. Life Sci. 2004, 61:1562-1578.
9. Hirano Y., Hendil K.B., Yashiroda H., Iemura S., Nagane R., Hioki Y., Natsume T., Tanaka K., Murata S. A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes. Nature 2005, 437:1381-1385.
10. Murata S., Yashiroda H., Tanaka K. Molecular mechanisms of proteasome assembly. Nat. Rev. Mol. Cell Biol. 2009, 10:104-115.
11. Tai H.C., Schuman E.M. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat. Rev. Neurosci. 2008, 9:826-838.
12. Dahlmann B. Role of proteasomes in disease. BMC Biochem. 2007, 8(Suppl. 1):S3.
13. Loscher M., Fortschegger K., Ritter G., Wostry M., Voglauer R., Schmid J.A., Watters S., Rivett A.J., Ajuh P., Lamond A.I., Katinger H., Grillari J. Interaction of U-box E3 ligase SNEV with PSMB4, the beta7 subunit of the 20S proteasome. Biochem. J. 2005, 388:593-603.
14. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
15. Nonaka T., Hasegawa M. A cellular model to monitor proteasome dysfunction by alpha-synuclein. Biochemistry 2009, 48:8014-8022.
16. Li X., Kusmierczyk A.R., Wong P., Emili A., Hochstrasser M. beta-Subunit appendages promote 20S proteasome assembly by overcoming an Ump1-dependent checkpoint. EMBO J. 2007, 26:2339-2349.
17. Marques A.J., Glanemann C., Ramos P.C., Dohmen R.J. The C-terminal extension of the beta7 subunit and activator complexes stabilize nascent 20S proteasomes and promote their maturation. J. Biol. Chem. 2007, 282:34869-34876.
18. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., Choi P., Wolozin B., Farrer M., Hardy J., Cookson M.R. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002, 36:1007-1019.
19. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 2003, 278:11753-11759.
20. Zhang N.Y., Tang Z., Liu C.W. alpha-Synuclein protofibrils inhibit 26S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J. Biol. Chem. 2008, 283:20288-20298.
21. Um J.W., Im E., Lee H.J., Min B., Yoo L., Yoo J., Lubbert H., Stichel-Gunkel C., Cho H.S., Yoon J.B., Chung K.C. Parkin directly modulates 26S proteasome activity. J. Neurosci. 2010, 30:11805-11814.